2116 related articles for article (PubMed ID: 19920054)
21. Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life.
Befrits R; Wikman O; Blomquist L; Hjortswang H; Hammarlund P; Bajor A; Klintman D; Blom H
Scand J Gastroenterol; 2013 Sep; 48(9):1027-32. PubMed ID: 23889159
[TBL] [Abstract][Full Text] [Related]
22. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial.
Seid MH; Derman RJ; Baker JB; Banach W; Goldberg C; Rogers R
Am J Obstet Gynecol; 2008 Oct; 199(4):435.e1-7. PubMed ID: 18928998
[TBL] [Abstract][Full Text] [Related]
23. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
van Veldhuisen DJ; Ponikowski P; van der Meer P; Metra M; Böhm M; Doletsky A; Voors AA; Macdougall IC; Anker SD; Roubert B; Zakin L; Cohen-Solal A;
Circulation; 2017 Oct; 136(15):1374-1383. PubMed ID: 28701470
[TBL] [Abstract][Full Text] [Related]
24. Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients With Acute Isovolemic Anemia Following Gastrectomy: The FAIRY Randomized Clinical Trial.
Kim YW; Bae JM; Park YK; Yang HK; Yu W; Yook JH; Noh SH; Han M; Ryu KW; Sohn TS; Lee HJ; Kwon OK; Ryu SY; Lee JH; Kim S; Yoon HM; Eom BW; Choi MG; Kim BS; Jeong O; Suh YS; Yoo MW; Lee IS; Jung MR; An JY; Kim HI; Kim Y; Yang H; Nam BH;
JAMA; 2017 May; 317(20):2097-2104. PubMed ID: 28535237
[TBL] [Abstract][Full Text] [Related]
25. Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia.
Cooper TJ; Anker SD; Comin-Colet J; Filippatos G; Lainscak M; Lüscher TF; Mori C; Johnson P; Ponikowski P; Dickstein K
Am J Cardiol; 2016 May; 117(9):1482-7. PubMed ID: 27015889
[TBL] [Abstract][Full Text] [Related]
26. Anemia and iron deficiency--new therapeutic targets in heart failure?
Dec GW
N Engl J Med; 2009 Dec; 361(25):2475-7. PubMed ID: 19920053
[No Abstract] [Full Text] [Related]
27. Are hematinic deficiencies the cause of anemia in chronic heart failure?
Witte KK; Desilva R; Chattopadhyay S; Ghosh J; Cleland JG; Clark AL
Am Heart J; 2004 May; 147(5):924-30. PubMed ID: 15131553
[TBL] [Abstract][Full Text] [Related]
28. A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain.
Comín-Colet J; Rubio-Rodríguez D; Rubio-Terrés C; Enjuanes-Grau C; Gutzwiller FS; Anker SD; Ponikowski P
Rev Esp Cardiol (Engl Ed); 2015 Oct; 68(10):846-51. PubMed ID: 25649970
[TBL] [Abstract][Full Text] [Related]
29. Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis.
Gutzwiller FS; Pfeil AM; Comin-Colet J; Ponikowski P; Filippatos G; Mori C; Braunhofer PG; Szucs TD; Schwenkglenks M; Anker SD
Int J Cardiol; 2013 Oct; 168(4):3878-83. PubMed ID: 23870642
[TBL] [Abstract][Full Text] [Related]
30. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
[TBL] [Abstract][Full Text] [Related]
31. Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
Mentz RJ; Garg J; Rockhold FW; Butler J; De Pasquale CG; Ezekowitz JA; Lewis GD; O'Meara E; Ponikowski P; Troughton RW; Wong YW; She L; Harrington J; Adamczyk R; Blackman N; Hernandez AF;
N Engl J Med; 2023 Sep; 389(11):975-986. PubMed ID: 37632463
[TBL] [Abstract][Full Text] [Related]
32. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease.
Evstatiev R; Alexeeva O; Bokemeyer B; Chopey I; Felder M; Gudehus M; Iqbal T; Khalif I; Marteau P; Stein J; Gasche C;
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):269-77. PubMed ID: 23078888
[TBL] [Abstract][Full Text] [Related]
33. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study.
Van Craenenbroeck EM; Conraads VM; Greenlaw N; Gaudesius G; Mori C; Ponikowski P; Anker SD
Eur J Heart Fail; 2013 Jul; 15(7):756-62. PubMed ID: 23639779
[TBL] [Abstract][Full Text] [Related]
34. Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia.
Mishra V; Gandhi K; Roy P; Hokabaj S; Shah KN
J Nepal Health Res Counc; 2017 Sep; 15(2):96-99. PubMed ID: 29016575
[TBL] [Abstract][Full Text] [Related]
35. Changes in myocardial iron content following administration of intravenous iron (Myocardial-IRON): Study design.
Miñana G; Cardells I; Palau P; Llàcer P; Fácila L; Almenar L; López-Lereu MP; Monmeneu JV; Amiguet M; González J; Serrano A; Montagud V; López-Vilella R; Valero E; García-Blas S; Bodí V; de la Espriella-Juan R; Sanchis J; Chorro FJ; Bayés-Genís A; Núñez J;
Clin Cardiol; 2018 Jun; 41(6):729-735. PubMed ID: 29607528
[TBL] [Abstract][Full Text] [Related]
36. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
Comin-Colet J; Lainscak M; Dickstein K; Filippatos GS; Johnson P; Lüscher TF; Mori C; Willenheimer R; Ponikowski P; Anker SD
Eur Heart J; 2013 Jan; 34(1):30-8. PubMed ID: 22297124
[TBL] [Abstract][Full Text] [Related]
37. Iron Deficiency in Heart Failure: An Overview.
von Haehling S; Ebner N; Evertz R; Ponikowski P; Anker SD
JACC Heart Fail; 2019 Jan; 7(1):36-46. PubMed ID: 30553903
[TBL] [Abstract][Full Text] [Related]
38. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh T; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD;
Eur Heart J; 2015 Mar; 36(11):657-68. PubMed ID: 25176939
[TBL] [Abstract][Full Text] [Related]
39. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study.
Viethen T; Gerhardt F; Dumitrescu D; Knoop-Busch S; ten Freyhaus H; Rudolph TK; Baldus S; Rosenkranz S
Int J Cardiol; 2014 Aug; 175(2):233-9. PubMed ID: 24880481
[TBL] [Abstract][Full Text] [Related]
40. Efficacy, safety and prognostic benefit of intravenous iron therapy with ferric carboxymaltose in patients with heart failure and left ventricular dysfunction.
Robles-Mezcua A; González-Cruces N; Ruiz-Salas A; Morcillo-Hidalgo L; Robledo-Carmona J; Gómez-Doblas JJ; de Teresa E; García-Pinilla JM
Int J Cardiol; 2016 Jan; 202():118-20. PubMed ID: 26397399
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
